Form 4: Korro Bio Director Receives Stock Option Grant

Director Jean-Francois Formela was granted 14,677 stock options in Korro Bio, Inc. as part of standard director compensation.

Summary

• Director Jean-Francois Formela received a grant of 14,677 stock options on June 10, 2026.
• The options have an exercise price of $10.59 per share.
• The options are set to expire on June 9, 2036.
• The grant is subject to a one-year vesting schedule tied to continued service as a non-employee director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $10.59 exercise price.

Future Outlook

The options vest in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, particularly for companies in the clinical development stage.

Comparison to Industry Standards

• The grant size and vesting terms are consistent with standard corporate governance practices for mid-cap biotechnology firms.
• The use of one-year cliff vesting is a common retention mechanism for board members in the life sciences industry.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of June 10, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Korro Bio, KRRO, Form 4, Insider Trading, Stock Options, Director Compensation